CLEARPOINT NEURO DL-,01

Clearpoint Neuro reported Q2 2026 revenue of $10.9m (expectation $12.73m) and an adjusted loss of $0.38 per share (expectation -$0.29), after which the stock fell about 15.5% in after‑hours trading to $13. Gross margin improved slightly to 62%, while selling, marketing, R&D and administrative expenses rose significantly. Cash and equivalents were $29.4m as of June 30, and management expects 2026 revenue of $48–52m. Long‑term growth drivers include the recently acquired CAL facility, robotics and focused ultrasound, though their commercial benefits are largely expected only in 2027. » Więcej na de.investing.com

Clearpoint Neuro shares rose about 26% in afternoon trading after the FDA gave UniQure the green light for an accelerated regulatory pathway for AMT-130. The agency allowed three-year Phase I/II data to serve as the basis for a BLA filing; submission is planned for Q3 2026. AMT-130 is delivered into the brain using Clearpoint's navigation system and SmartFlow cannula, so a potential approval would directly strengthen commercial use of the Clearpoint platform. The FDA also designated AMT-130 as RMAT, Breakthrough Therapy and Fast Track, underscoring the therapy's significance for treating Huntington's disease. » Więcej na de.investing.com

ClearPoint Neuro has received CE marking in Europe for its high‑speed drilling system Velocity Alpha MR, in addition to existing FDA 510(k) clearance in the U.S. The pneumatic system, manufactured by Adeor Medical AG, is cleared for integration with the SmartFrame navigation platform in MRI environments and the OR at magnetic field strengths up to 3.0 Tesla and reaches speeds up to 80,000 rpm. The company reports a gross margin of 61%; the stock recently rose by more than 10%, although an InvestingPro analysis points to possible overvaluation while analysts still see upside potential. » Więcej na de.investing.com